Challenge in the treatment of neuropsychiatric diseases

Neuropsychiatric diseases (e.g. schizophrenia, depression, anxiety, dementia) are common and cause enormous emotional and economic burden to patients, relatives, caregivers, and to the community.

The market for drugs directed against neuropsychiatric diseases is very large (i.e. 80.5 billion US$ sales in 2010) and still growing. However, major pharmaceutical companies are disengaging from research and drug-discovery programs related to neuropsychiatric diseases because the current strategies, mostly based on models of animal behavior) have failed to identify novel and significantly improved drugs (Nature 480, 161-162, 2011).

The discrepancy between the urgent need for improved therapeutic compounds along with their large market potential on the one hand, and the current lack of significant development of novel and improved drugs on the other, warrants the need for alternative strategies aimed at identifying druggable targets related to neuropsychiatric disease.

GeneGuide offers a solution to this problem.


Copyright © GeneGuide 2013-2017

Finding new treatments

through human genomics